Genetic Immunity is a US clinical-stage biotechnology company focusing on the discovery, development and commercialization of a new class of therapeutic vaccines ("Immune Therapies") for the treatment of chronic viral infections (HIV, HPV), cancer and allergies. Our Immune Therapies are designed to intensify and boost specific immune response to modify or control these presently incurable diseases. We believe our products will allow people to live better, healthier and longer lives.
Our proprietary immunotherapy platform is composed of an pDNA (plasmid DNA) expressing multiple disease specific antigens, a nanomedicine formulation encapsulating the pDNA and a topical administration device which targets the formulation transdermally to dendritic (Langerhans) cells of the skin. Our platform technologies support the rapid and cost-effective development of novel biologic products for several indications and provides tools for the selection of an optimal, patient specific treatment regimen.
Our Lead Product Candidate, a therapeutic vaccine for the treatment of HIV is effective in boosting immune response to kill HIV-infected cells. Our preclinical, Phase I, Phase I/II and Phase II trials have demonstrated HIV-specific T-cells immune response and boosting, and the killing of HIV-infected cells. DermaVir has an excellent safety profile. Our goal is to provide DermaVir as a co-treatment option to antiretroviral therapy (ART), and, upon the completion of an additional clinical trial, to demonstrate efficacy in ART resistant patients, thereby opening a safe, effective new treatment paradigm.
In addition to HIV we also work on an extensive pipeline including therapeutic treatments for cancer, the human papillomavirus, MAGE, allergies and more.
Please see our pipeline of virus-associated cancers and warts in discovery phase section of the website.
Verified 0%
Attention. There is a risk that unverified members are not actually members of the team
Verified 0%
Attention. There is a risk that unverified members are not actually members of the team
This offer is based solely on information provided by the offeror and other publicly available sources.
The token sale or exchange event is completely independent of ICOholder. ICOholder is not involved in any way, including technical support or promotion.
We list token sales from entities with which we have no relationship to help users track overall activity within the token sector. This information is not intended as advice, and you should seek professional or specialist guidance or conduct your own due diligence before making any decisions based on our content.
Any terms and conditions regarding token acquisition are solely between contributors and the token issuer. ICOholder is not the seller of these tokens.
ICOholder is not legally responsible for any representations made by third parties about any token sale. Any claims for breach of contract must be directed against the listed token issuing entity.
If you have concerns about the nature, legality, or propriety of a token sale or the involved individuals, please contact info@icoholder.com with detailed information.